February 24, 2009 - The Medipattern Corp. and NAVIX Diagnostix Inc., a leading provider of vascular ultrasound outsourcing solutions in the northeastern U.S., said that NAVIX will collect data for the development of Medipattern's vascular imaging tool, VasculariQ.
The American Heart Association cites an estimated 80,700,000 American adults (one in three) have one or more types of cardiovascular disease (CVD) and the statistics echo throughout the global population. Medipattern recently announced an agreement with GE Healthcare to create a set of image quantification tools to help physicians visualize plaque and other conditions that can block the vascular system. Vascular diseases are estimated to be among the highest causes of lifestyle impairment, including stroke, amputation and heart attack.
"When I saw the proof of concept results from CADenza, I knew that Medipattern's technology approach for VasculariQ had the potential to change the way that we plan intervention for vascular diseases,” said Bob Kane, Senior Vice President of Clinical Services and Business Development of NAVIX. ”The technology may also have the ability to predict the potential development of adverse events. Currently, treatment options used to address vascular disease are lifestyle modifications, like smoking cessation, diet and exercise, medication; minimally invasive procedures including angioplasty and stenting; and open surgery. Patient care is most improved when physicians are able to determine the best treatment option; however choosing the best method may be problematic. With VasculariQ, Medipattern's tool set can assist physicians to make a more informed decision about treatment options for the millions of people diagnosed with vascular diseases. Under the agreement Medipattern will receive real-time ultrasound images and supporting information for known vascular diseases."
For more information: www.medipattern.com, www.navixdiagnostics.com
April 24, 2024 
